BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA
Blinatumomab, a CD19-CD3 bispecific T cell engager (BiTE), has two recombinant single-chain variable fragments that temporarily link CD3+ T cells and CD19+ B cells, leading to the T cell-mediated lysis of neoplastic B cells. Improved minimal residual disease (MRD)-negative response rates and long-t...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2024-08-01
|
Series: | Mediterranean Journal of Hematology and Infectious Diseases |
Subjects: | |
Online Access: | https://www.mjhid.org/mjhid/article/view/5793 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832543434754228224 |
---|---|
author | Ugo Testa Elvira Pelosi Germana Castelli Patrizia Chiusolo |
author_facet | Ugo Testa Elvira Pelosi Germana Castelli Patrizia Chiusolo |
author_sort | Ugo Testa |
collection | DOAJ |
description |
Blinatumomab, a CD19-CD3 bispecific T cell engager (BiTE), has two recombinant single-chain variable fragments that temporarily link CD3+ T cells and CD19+ B cells, leading to the T cell-mediated lysis of neoplastic B cells. Improved minimal residual disease (MRD)-negative response rates and long-term overall survival have been observed in B-ALL patients who received this drug. These therapeutic successes have led to FDA approval for refractory/relapsed and MRD-positive B-ALL patients. Furthermore, recent studies in newly diagnosed B-ALL patients have led in Philadelphia chromosome-positive patients to the development of chemotherapy-free regimens based on tyrosine kinase inhibitors plus Blinatumomab and in Philadelphia chromosome-negative patients to improvement in outcomes using chemotherapy regimens that have incorporated Blinatumomab in the consolidation phase of treatment.
|
format | Article |
id | doaj-art-880f4b38f3164cb48f22c1876c312b46 |
institution | Kabale University |
issn | 2035-3006 |
language | English |
publishDate | 2024-08-01 |
publisher | PAGEPress Publications |
record_format | Article |
series | Mediterranean Journal of Hematology and Infectious Diseases |
spelling | doaj-art-880f4b38f3164cb48f22c1876c312b462025-02-03T11:44:24ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062024-08-0116110.4084/MJHID.2024.070BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIAUgo Testa0Elvira Pelosi1Germana Castelli2Patrizia Chiusolo3ISSIstituto Superiore SanitàIstituto Superiore SanitàPoliclinico Gemelli, Universitò Cattolica, Medicina. Blinatumomab, a CD19-CD3 bispecific T cell engager (BiTE), has two recombinant single-chain variable fragments that temporarily link CD3+ T cells and CD19+ B cells, leading to the T cell-mediated lysis of neoplastic B cells. Improved minimal residual disease (MRD)-negative response rates and long-term overall survival have been observed in B-ALL patients who received this drug. These therapeutic successes have led to FDA approval for refractory/relapsed and MRD-positive B-ALL patients. Furthermore, recent studies in newly diagnosed B-ALL patients have led in Philadelphia chromosome-positive patients to the development of chemotherapy-free regimens based on tyrosine kinase inhibitors plus Blinatumomab and in Philadelphia chromosome-negative patients to improvement in outcomes using chemotherapy regimens that have incorporated Blinatumomab in the consolidation phase of treatment. https://www.mjhid.org/mjhid/article/view/5793BlinatumomabALLImmunotherapy; bispecific antibody |
spellingShingle | Ugo Testa Elvira Pelosi Germana Castelli Patrizia Chiusolo BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA Mediterranean Journal of Hematology and Infectious Diseases Blinatumomab ALL Immunotherapy; bispecific antibody |
title | BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA |
title_full | BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA |
title_fullStr | BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA |
title_full_unstemmed | BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA |
title_short | BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA |
title_sort | blinatumomab in the therapy of acute b lymphoid leukemia |
topic | Blinatumomab ALL Immunotherapy; bispecific antibody |
url | https://www.mjhid.org/mjhid/article/view/5793 |
work_keys_str_mv | AT ugotesta blinatumomabinthetherapyofacuteblymphoidleukemia AT elvirapelosi blinatumomabinthetherapyofacuteblymphoidleukemia AT germanacastelli blinatumomabinthetherapyofacuteblymphoidleukemia AT patriziachiusolo blinatumomabinthetherapyofacuteblymphoidleukemia |